Concord Biotech
Ticker > Company >

Concord Biotech share price

Concord Biotech Ltd.

NSE: CONCORDBIO BSE: 543960 SECTOR: Pharmaceuticals & Drugs  75.53 K   112   22

1636.15
+15.30 (0.94%)
BSE: 17 Sep 04:01 PM

Price Summary

Today's High

₹ 1640

Today's Low

₹ 1611

52 Week High

₹ 2658

52 Week Low

₹ 1370.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 17116.78 Cr.

Enterprise Value

₹ 17115.98 Cr.

No. of Shares

10.46 Cr.

P/E

47.91

P/B

9.23

Face Value

₹ 1

Div. Yield

0.65 %

Book Value (TTM)

₹  177.34

CASH

₹ 1.18 Cr.

DEBT

₹ 0.38 Cr.

Promoter Holding

44.08 %

EPS (TTM)

₹  34.15

Sales Growth

18.01%

ROE

22.35 %

ROCE

29.72%

Profit Growth

22.39 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year18.01%
3 Year18.96%
5 Year18.56%

Profit Growth

1 Year22.39%
3 Year27.83%
5 Year17.16%

ROE%

1 Year22.35%
3 Year21.28%
5 Year21.48%

ROCE %

1 Year29.72%
3 Year28.36%
5 Year28.01%

Debt/Equity

0.0002

Price to Cash Flow

70

Interest Cover Ratio

477.0252

CFO/PAT (5 Yr. Avg.)

0.85000338039744

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 44.08 0.00
Mar 2025 44.08 0.00
Dec 2024 44.08 0.00
Sep 2024 44.08 0.00
Jun 2024 44.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 27.8266509455765% for the Past 3 years.
  • The company has shown a good revenue growth of 18.9562149725362% for the Past 3 years.
  • The company has significantly decreased its debt by 5.8487 Cr.
  • Company has been maintaining healthy ROE of 21.2772333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.3636% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 477.0252.
  • The Company has been maintaining an effective average operating margins of 43.4332640819245% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 76.629 days.
  • Company has a healthy liquidity position with current ratio of 6.1677.

 Limitations

  • The company is trading at a high PE of 47.91.
  • The company is trading at a high EV/EBITDA of 32.0363.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 215.8 310.18 244.22 429.88 203.99
Total Expenditure 134.52 173.5 146.27 239.46 142.59
Operating Profit 81.28 136.68 97.95 190.42 61.4
Other Income 10.31 10.03 14.73 9.38 13.68
Interest 0.24 0.1 0.1 0.1 0.06
Depreciation 13.18 13.31 13.26 14.62 17.78
Exceptional Items 0 0 0 0 0
Profit Before Tax 78.17 133.29 99.32 185.09 57.24
Tax 19.93 34.59 25.23 43.16 14.67
Profit After Tax 58.24 98.7 74.09 141.94 42.57
Adjusted EPS (Rs) 5.57 9.43 7.08 13.57 4.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 616.94 712.93 853.17 1016.94 1200.09
Total Expenditure 289.01 439.01 504.59 584.75 693.24
Operating Profit 327.93 273.93 348.58 432.19 506.84
Other Income 13.81 23.42 35.31 33.78 44.45
Interest 1.05 6.13 9.8 3.18 1.04
Depreciation 27.52 50.05 54.03 53.59 54.37
Exceptional Items 0 0 0 0 0
Profit Before Tax 313.17 241.16 320.05 409.19 495.88
Tax 77.83 62.59 81.93 104.46 122.91
Net Profit 235.29 178.57 238.13 304.73 372.96
Adjusted EPS (Rs.) 22.5 17.07 22.76 29.13 35.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 9.51 9.51 10.46 10.46 10.46
Total Reserves 990.16 1097.65 1281.52 1514.79 1802.18
Borrowings 56.25 31.25 6.24 0 0
Other N/C liabilities 151.37 212.23 25.9 31.91 37.47
Current liabilities 105.74 151.89 190.53 142.16 184.06
Total Liabilities 1313.03 1502.53 1514.65 1699.32 2034.18
Assets
Net Block 546.22 572.98 592.98 575.32 794.69
Capital WIP 17.95 74.16 172.7 211.48 50.13
Intangible WIP 0 0 0 0 0.53
Investments 0.67 0.92 0.79 0.67 18.65
Loans & Advances 140.61 220.99 11.61 12.81 12.01
Other N/C Assets 0.45 0.82 8.87 2.81 22.93
Current Assets 607.15 632.67 727.7 896.23 1135.24
Total Assets 1313.03 1502.53 1514.65 1699.32 2034.18
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 313.17 241.16 320.05 409.19 495.88
Adjustment 17.59 49.16 48.51 40.8 28.82
Changes in Assets & Liabilities -88.77 -22.06 -52.29 -81.18 -170.76
Tax Paid -75.18 -60.78 -70.28 -103.35 -109.42
Operating Cash Flow 166.81 207.47 246 265.47 244.52
Investing Cash Flow -195.2 -111.79 -157.95 -154.61 -159.99
Financing Cash Flow 31.12 -100.16 -85.22 -99.21 -98.77
Net Cash Flow 2.74 -4.48 2.83 11.64 -14.24

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 44.08 44.08 44.08 44.08 44.08
ankur sudhir vaid 0.56 0.56 0.56 0.56 0.56
manju vaid 9.55 9.55 9.55 9.55 9.55
sonal kumra 0.07 0.07 0.07 0.07 0.07
sudhir vaid 28.84 28.84 28.84 28.84 28.84
sudman consultants llp 4.54 4.54 4.54 4.54 4.54
vaid megha ankur 0.52 0.52 0.52 0.52 0.52
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 55.92 55.92 55.92 55.92 55.92
1575773 ontario inc 2.00 - 2.00 2.00 2.00
amal parikh - - 1.93 1.93 1.93
aryaman jhunjhunwaladiscr... - - - 8.03 8.03
aryavir jhunjhunwala disc... 8.03 8.03 8.03 8.03 8.03
axis max life insurance l... - - - 1.55 1.52
chanakya corporate servic... 1.11 1.11 1.11 1.11 1.11
government pension fund g... 2.68 2.56 2.79 2.98 2.66
nishtha jhunjhunwaladiscr... - - - 8.03 8.03
ravindra raichand dharams... 1.93 1.54 1.50 1.34 1.20
tata aia life insurance c... 1.93 1.89 1.95 1.55 1.55
hsbc small cap fund - 1.02 1.02 1.02 -
aryaman jhunjhunwala disc... 8.03 8.03 8.03 - -
invesco india flexi cap f... - 1.04 1.07 - -
max life insurance compan... - 1.91 1.93 - -
nishtha jhunjhunwala disc... 8.03 8.03 8.03 - -
amal n parikh 1.93 1.93 - - -
invesco india flex cap fu... 1.08 - - - -
llp 0.15 - - - -
max life insurance compan... 1.98 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q3FY24
Presentation Q1FY24

Company News

EU-GMP authorities conduct inspection at Concord Biotech’s API facility in Limbassi 21 Aug, 3:58 PM Concord Biotech informs about record date 8 Aug, 5:24 PM Concord Biotech - Quaterly Results 8 Aug, 4:44 PM Concord Biotech - Quaterly Results 8 Aug, 4:44 PM Concord Biotech - Quaterly Results 8 Aug, 4:44 PM Concord Biotech completes Russian GMP inspection 28 Jul, 3:00 PM Concord Biotech incorporates wholly owned subsidiary 23 Jul, 12:30 PM Concord Biotech informs about updates 18 Jul, 2:58 PM Concord Biotech informs about certificate 8 Jul, 9:57 AM Concord Biotech makes equity investment of $1,500 in Stellon Biotech Inc 2 Jul, 2:12 PM Concord Biotech gets EIR from USFDA for API facility at Dholka 24 Jun, 3:43 PM Concord Biotech - Quaterly Results 29 May, 7:28 PM Concord Biotech - Quaterly Results 29 May, 7:28 PM Concord Biotech gets final approval from USFDA for marketing Teriflunomide Tablets 9 Apr, 9:02 AM Concord Biotech commences production of injectable at Valthera facility 25 Mar, 2:30 PM Concord Biotech informs about closure of trading window 22 Mar, 3:49 PM Concord Biotech gets nod to make investment of Rs 6.10 crore in Clean Max Everglades 4 Mar, 2:22 PM Concord Biotech informs about analyst meet 1 Mar, 11:17 AM Concord Biotech informs about analyst meet 22 Feb, 10:03 AM Concord Biotech informs about transcripts of earnings call 21 Feb, 10:37 AM Concord Biotech reports marginal decline in Q3 consolidated net profit 14 Feb, 2:51 PM Concord Biotech informs about investor’s presentation 14 Feb, 12:19 PM Concord Biotech - Quaterly Results 13 Feb, 7:37 PM Concord Biotech - Quaterly Results 13 Feb, 7:37 PM Concord Biotech informs about earnings call 31 Jan, 5:18 PM Concord Biotech informs about board meeting 24 Jan, 12:30 PM Concord biotech to acquire 26% stake of Clean Max from CMEESPL 17 Jan, 2:42 PM Concord Biotech informs about share purchase agreement 16 Jan, 5:21 PM Concord Biotech informs about acquisition 12 Dec, 1:55 PM Concord Biotech informs about earnings call transcript 19 Nov, 12:26 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech informs about board meeting 6 Nov, 11:01 AM Concord Biotech informs about earnings call 6 Nov, 10:57 AM Concord Biotech informs about closure of trading window 25 Sep, 4:56 PM Concord Biotech informs about clarification on price movement 24 Sep, 2:58 PM Concord Biotec informs about investor meeting 30 Aug, 12:09 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech informs about voting results and scrutinizer report 2 Jul, 11:10 AM Concord Biotech informs about annual report 1 Jul, 2:41 PM Health Product Regulatory Authority issues EUGMP certificate to Concord Biotech’s Valthera facility 6 Jun, 12:27 PM Concord Biotech informs about earnings call transcript 4 Jun, 5:11 PM Concord Biotech informs about disclosures 29 May, 4:20 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech informs about earning call 21 May, 11:08 AM

Concord Biotech Stock Price Analysis and Quick Research Report. Is Concord Biotech an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Concord Biotech. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Concord Biotech has a PE ratio of 47.8878683090942 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Concord Biotech has ROA of 19.9794% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Concord Biotech has a Current ratio of 6.1677.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Concord Biotech has a ROE of 22.3473%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Concord Biotech has a Debt to Equity ratio of 0.0002 which means that the company has low proportion of debt in its capital.

  • Sales growth: Concord Biotech has reported revenue growth of 18.0097% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Concord Biotech for the current financial year is 42.2339332260022%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Concord Biotech is Rs 10.7 and the yield is 0.6568%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Concord Biotech is Rs 34.1527. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Concord Biotech in Ticker for free. Also, one can get the intrinsic value of Concord Biotech by using Valuation Calculators, which are available with a Finology ONE subscription. 

Concord Biotech FAQs

Q1. What is Concord Biotech share price today?
Ans: The current share price of Concord Biotech is Rs 1635.5.

Q2. What is the market capitalisation of Concord Biotech?
Ans: Concord Biotech has a market capitalisation of Rs 17109.9801642 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Concord Biotech?
Ans: The PE ratio of Concord Biotech is 47.8878683090942 and the P/B ratio of Concord Biotech is 9.2226524810937, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Concord Biotech share?
Ans: The 52-week high share price of Concord Biotech is Rs 2664, and the 52-week low share price of Concord Biotech is Rs 1345.

Q5. Does Concord Biotech pay dividends?
Ans: Currently, Concord Biotech pays dividends. Dividend yield of Concord Biotech is around 0.6568%.

Q6. What are the face value and book value of Concord Biotech shares?
Ans: The face value of Concord Biotech shares is Rs 1, while the book value per share of Concord Biotech is around Rs 177.3351. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Concord Biotech?
Ans: Concord Biotech has a total debt of Rs 0.3811 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Concord Biotech?
Ans: The ROE of Concord Biotech is 22.3473% and ROCE of Concord Biotech is 29.7154%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Concord Biotech a good buy for the long term?
Ans: The Concord Biotech long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Concord Biotech undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Concord Biotech appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Concord Biotech’s financials?
Ans: You can review Concord Biotech’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Concord Biotech

Concord Biotech Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Concord Biotech Ltd. is a renowned biotechnology company that specializes in the development and manufacturing of fermentation-based products. With a strong focus on research and development, the company has established itself as a leader in the biopharmaceutical and nutraceutical industries. Founded in the year XXXX, Concord Biotech has consistently delivered innovative solutions to its customers.

Concord Biotech Ltd. Stock Analysis – Share Price

The share price of Concord Biotech Ltd. reflects the market's perception of the company's future prospects. As a long-term stock investor, understanding the factors that influence the share price is crucial. At our website, you can monitor and analyze the historical share price movements of Concord Biotech Ltd. using our pre-built screening tools.

Concord Biotech Ltd. Stock Analysis – Balance Sheet

The balance sheet of Concord Biotech Ltd. provides insights into the company's financial position and its ability to meet its obligations. As a long-term investor, analyzing the balance sheet is essential to understand the company's assets, liabilities, and equity. At our website, you can access the company's annual reports for a comprehensive review of its balance sheet. Our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable fair value calculation for informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Annual Report

The annual report of Concord Biotech Ltd. provides comprehensive information about the company's financial performance, business strategies, and future outlook. At our website, you can download the annual reports of Concord Biotech Ltd. for a detailed analysis and better understanding of the company's operations.

Concord Biotech Ltd. Stock Analysis – Dividend

Dividends are an important consideration for long-term investors as they provide a regular income stream. Concord Biotech Ltd. has a consistent track record of rewarding its shareholders through dividends. By analyzing the company's dividend history, investors can assess its financial stability and the potential for future dividend payouts.

Concord Biotech Ltd. Stock Analysis – Quarterly Result

Analyzing the quarterly results of Concord Biotech Ltd. allows investors to gauge the company's financial performance on a regular basis. Our website provides access to the quarterly reports of Concord Biotech Ltd., enabling investors to stay updated with the latest financial results and make informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Stock Price

The stock price of Concord Biotech Ltd. is influenced by various factors, including market sentiment, industry trends, and the company's financial performance. By monitoring the stock price movements and trends, investors can identify potential buying or selling opportunities. Our website provides a price chart for Concord Biotech Ltd., allowing investors to visualize the historical stock price data.

Concord Biotech Ltd. Stock Analysis – Price Chart

Our website offers a price chart feature that allows investors to analyze the historical stock price movements of Concord Biotech Ltd. This tool enables users to identify trends, patterns, and potential price levels for informed decision-making.

Concord Biotech Ltd. Stock Analysis – News

Keeping track of the latest news and developments related to Concord Biotech Ltd. is essential for investors. Our website provides a dedicated news section where users can access the latest news articles and updates about the company. Staying informed about industry trends, regulatory changes, and company-specific news is crucial for effective stock analysis.

Concord Biotech Ltd. Stock Analysis – Concall and Transcripts

Concalls (conference calls) are an important source of information for investors as they provide insights into a company's performance, strategies, and future outlook. At our website, you can access the concall transcripts of Concord Biotech Ltd., allowing you to stay updated with the management's discussions and analysis of the company's operations.

Concord Biotech Ltd. Stock Analysis – Investor Presentations

Investor presentations play a significant role in understanding a company's business model, growth plans, and strategic initiatives. Concord Biotech Ltd. provides investor presentations that offer valuable insights into the company's operations and opportunities. By analyzing these presentations, investors can gain a deeper understanding of Concord Biotech Ltd.'s growth prospects and investment potential.

Concord Biotech Ltd. Stock Analysis – Promoters and Shareholders

The promoters and major shareholders of Concord Biotech Ltd. play a crucial role in shaping the company's direction and decision-making. Understanding the key stakeholders can provide insights into their commitment to the company's success. At our website, you can access information about the promoters and major shareholders of Concord Biotech Ltd., helping you evaluate their influence on the company's operations and future plans.

In conclusion, Concord Biotech Ltd. presents an attractive opportunity for long-term stock investors seeking to analyze the company's performance and prospects. Our website offers various tools and resources, including pre-built screening tools, annual reports, concall transcripts, investor presentations, and premium features like fair value calculation using DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis. Stay informed and make informed investment decisions with our comprehensive stock analysis tools and information on Concord Biotech Ltd. 

Concord Biotech Balance Sheet Overview

Concord Biotech's Growing Reserves

Analyzing Concord Biotech's balance sheet data, it is evident that the company has significantly augmented its total reserves, from Rs. 760.57 Cr in March 2020 to a robust Rs. 1,514.79 Cr by March 2024. This growth trajectory underlines the company's ability to bolster its financial stability over the years.

Concord Biotech's Debt Management

A remarkable aspect of Concord Biotech's financial health is its effective debt management. The company has methodically reduced its borrowings from Rs. 35.53 Cr in March 2020 to an impressive zero by March 2024. This indicates a strategic focus on minimizing leverage and enhancing equity financing.

Concord Biotech's Asset Allocation

On the assets front, Concord Biotech has shown a consistent increase in its current assets, from Rs. 646.76 Cr in March 2020 to Rs. 896.23 Cr by March 2024. This growth in current assets, alongside investments in Net Block and Capital WIP, underscores the company’s commitment to expanding its operational capacities and asset base.

This data represents an analysis for the Standalone Balance Sheet of Concord Biotech. It offers crucial insights for investors looking at stock screening processes, thereby facilitating informed investment decisions in sectors that Concord Biotech operates within.

Read More
X